港股收评：恒指涨0.58%、科指涨0.84%，科技及大金融股多数走高，券商股活跃

Market Performance - The Hong Kong stock market opened lower but maintained an upward trend, with the Hang Seng Index closing up 0.58% at 26,085.08 points [1] - The Hang Seng Tech Index rose 0.84% to 5,662.46 points, while the China Enterprises Index increased by 1.01% to 9,198.3 points [1] - Major financial stocks saw significant gains, with China Ping An rising over 6% and other insurance stocks also increasing by more than 5% [1] Company News - Country Garden (02007.HK) has completed its debt restructuring, reducing its debt by over 90 billion yuan [2] - Longfor Group (03380.HK) has received debt restructuring offers for bonds with a total face value of 13.66 billion yuan [3] - Greentown China (03900.HK) reported a total contract sales amount of approximately 223.5 billion yuan for the first 11 months, a year-on-year decrease of 9.44% [4] - Hongyang Real Estate (01996.HK) reported a cumulative contract sales amount of 4.181 billion yuan for the first 11 months, down 47.87% year-on-year [5] - Sunac China (01918.HK) achieved a contract sales amount of approximately 33.89 billion yuan for the first 11 months, a decrease of 25.34% year-on-year [6] - China Overseas Macro Holdings (00081.HK) reported a cumulative contract sales amount of 29.615 billion yuan for the first 11 months, down 16.6% year-on-year [7] Pharmaceutical and Biotechnology Developments - Stone Four Pharmaceutical Group (02005.HK) received approval from the National Medical Products Administration for the registration of Bilastine and Picosulfate Sodium as raw materials for listed formulations [8] - Kelun-Botai Biotech (06990.HK) has entered into a strategic partnership with Crescent to jointly develop and commercialize cancer treatment methods, with an upfront payment of 80 million USD and potential milestone payments of up to 1.25 billion USD [8] Market Outlook - Guoyuan International notes uncertainty in the Federal Reserve's decision-making for December, influenced by recent hawkish tones from the Bank of Japan, which may create short-term external disturbances for the Hong Kong market [10] - According to CMB International, the pharmaceutical industry is expected to see a key turning point in 2025, with a stable outlook continuing into 2026 [10] - According to Everbright Securities, the Hang Seng Index's current P/E ratio is above the average of the past five years, indicating a recovery in overall valuation, while the tech index has room for growth [11]